Genomic and immune profiling of prognostic risk groups in IgM gammopathy reveals novel biomarkers beyond MYD88 L265P by David F. Moreno, David F. Moreno, Ferran Nadeu, Ferran Nadeu, Fara Brasó-Maristany, Fara Brasó-Maristany, Fara Brasó-Maristany, Sergi Vaqué, Sara Paz, Joan Mañé, Oriol Cardús, Elena Medina, Ester Lozano, Ester Lozano, Luis Gerardo Rodríguez-Lobato, Luis Gerardo Rodríguez-Lobato, Anna de Daniel, Anna de Daniel, Natalia Tovar, María T. Cibeira, Joan Bladé, Laura Rosiñol, Aleix Prat, Aleix Prat, Aleix Prat, Aleix Prat, Dolors Colomer, Dolors Colomer, Dolors Colomer, Carlos Fernández de Larrea, Carlos Fernández de Larrea

Get full text

ZMYND8 drives HER2 antibody resistance in breast cancer via lipid control of IL-27 by Yong Wang, Yanan Wang, Lei Bao, Goncalo Vale, Jeffrey G. McDonald, Yisheng Fang, Yan Peng, Ashwani Kumar, Chao Xing, Fara Brasó-Maristany, Aleix Prat, Carlos L. Arteaga, Yingfei Wang, Weibo Luo

Get full text

Publisher Correction: ZMYND8 drives HER2 antibody resistance in breast cancer via lipid control of IL-27 by Yong Wang, Yanan Wang, Lei Bao, Goncalo Vale, Jeffrey G. McDonald, Yisheng Fang, Yan Peng, Ashwani Kumar, Chao Xing, Fara Brasó-Maristany, Aleix Prat, Carlos L. Arteaga, Yingfei Wang, Weibo Luo

Get full text

Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy by Sonia Pernas, Esther Sanfeliu, Guillermo Villacampa, Javier Salvador, Antonia Perelló, Xavier González, Begoña Jiménez, María Merino, Patricia Palacios, Tomás Pascual, Emilio Alba, Lorea Villanueva, Samyukta Chillara, Juan Manuel Ferrero-Cafiero, Patricia Galvan, Aleix Prat, Eva Ciruelos

Get full text

Deciphering the transcriptomic landscape of early HR+/HER2− breast cancer in very young women by Iris Garrido‐Cano, Marta Tapia, Juan Carbonell, Carlos Peña, Sandra Torres‐Ruiz, Anna Ágreda‐Roca, Ana Lameirinhas, Cristina Tebar, Octavio Burgués, Cristina Hernando, Ana Lluch, Fara Brasó‐Maristany, Aleix Prat, Begoña Bermejo, María Teresa Martínez, Juan Miguel Cejalvo

Get full text

Molecular characterisation of the residual disease after neoadjuvant endocrine therapy in ER+/HER2- breast cancer uncovers biomarkers of tumour response by Joanna I. López-Velazco, Sara Manzano, Kepa Elorriaga, Maria Otaño, Ainhara Lahuerta, Luis Álvarez, Inge Etxabe, Miren Huarte, Elvira Buch, Julia Gimenez, Vanesa Quiroga, Marta Fernandez, Sofía Aragón, Laia Paré, Aleix Prat, Isabel Álvarez-López, Maria M. Caffarel, Ander Urruticoechea

Get full text

Corrigendum to “Prognostic Expression Signature of RB1, PTEN, and TP53 Genes in Patients with Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Receptor Pathway In... by Marta Garcia de Herreros, Natalia Jiménez, Leonardo Rodríguez-Carunchio, Eva Lillo, Mercedes Marín-Aguilera, Laura Ferrer-Mileo, Caterina Aversa, Samuel García-Esteve, Joan Padrosa, Isabel Trias, Laia Fernández-Mañas, Albert Font, Isabel Chirivella, Mariona Figols, Miguel Ángel Climent, Aleix Prat, Òscar Reig, Begoña Mellado

Get full text

Selective tubulin-binding drugs induce pericyte phenotype switching and anti-cancer immunity by Bo He, Kira H Wood, Zhi-jie Li, Judith A Ermer, Ji Li, Edward R Bastow, Suraj Sakaram, Phillip K Darcy, Lisa J Spalding, Cameron T Redfern, Jordi Canes, Mafalda Oliveira, Aleix Prat, Javier Cortes, Erik W Thompson, Bruce A Littlefield, Andrew Redfern, Ruth Ganss

Get full text

Prognostic Expression Signature of RB1, PTEN, and TP53 Genes in Patients with Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors by Marta Garcia de Herreros, Natalia Jiménez, Leonardo Rodríguez-Carunchio, Eva Lillo, Mercedes Marín-Aguilera, Laura Ferrer-Mileo, Caterina Aversa, Samuel García-Esteve, Joan Padrosa, Isabel Trias, Laia Fernández-Mañas, Albert Font, Isabel Chirivella, Mariona Figols, Miguel Ángel Climent, Aleix Prat, Òscar Reig, Begoña Mellado

Get full text

Frequency of driver oncogenic alterations in NSCLC and estimated indoor radon exposure in Europe (RADON EUROPE study) by Miguel García-Pardo, Marta García de Herreros, Edouard Auclin, Miquel Ferriol-Galmes, Juan Carlos Laguna, Teresa Gorría, Gerard Caravaca, Joan Sart, Víctor Albarrán-Artahona, Rafael López-Castro, Cristina Teixidó, Giancarlo Castellano, Alex Martínez Bedmar, Ainara Arcocha, Laura Alcolea, Manuel Jiménez, Mario Bernabeu, David Delgado-Cano, Alejandro Navarro, Aleix Prat, Noemí Reguart, Javier Elio, Pilar Garrido, Natasha B. Leighl, Benjamin Besse, Laura Mezquita

Get full text

HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials WSG-ADAPT-HR+/HER2-, WSG-PlanB, and WSG-ADAPT-TN by Gilda Schmidt, Oleg Gluz, Matthias Christgen, Mattea Reinisch, Sherko Kümmel, Ulrike Nitz, Michael Braun, Bahriye Aktas, Kerstin Lüdtke-Heckenkamp, Helmut Forstbauer, Eva-Maria Grischke, Claudia Schumacher, Rolf Mahlberg, Wolfram Malter, Toralf Reimer, Benno Nuding, Andrea Stefek, Rachel Wuerstlein, Monika Graeser, Katarzyna Jóźwiak, Sandy Burmeister, Christine zu Eulenburg, Michael Lauseker, Cornelia Kolberg-Liedtke, Aleix Prat, Peter Schmid, Rick Baehner, Hans Heinrich Kreipe, Erich-Franz Solomayer, Nadia Harbeck, on behalf of the West German Stud y Group investigators

Get full text

HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab by Rodrigo Sánchez-Bayona, Olga Martínez-Sáez, Denys Romero-Romero, Elia Seguí, Esther Carcelero, Pablo Tolosa, Jesús Soberino, Manuel Alva, Tomás Pascual, Laura Lema, Isabel Garcia-Fructuoso, Maria Angeles Cobos-Fernandez, Maria Rey, Luis Manso, Angela Aguirre, Ainhoa Madariaga, Valeria Sirenko, Cristina González-Deza, Paula Blasco, Astrid Mayhua, Oleguer Castillo, Patricia Galván, Esther Sanfeliu, Guillermo Villacampa, Wesley Buckingham, Mercedes Marín-Aguilera, Laia Paré, Patricia Villagrasa, Charles M. Perou, Julia Maues, Fara Brasó-Maristany, Eva Ciruelos, Aleix Prat

Get full text